Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2001

View Archived Issues

Phase II trial of TH-9507 in type 2 diabetes cleared by FDA

NeuroSearch offers interim progress report

Hemosol given green light to proceed with Hemolink clinical program

FDA approval for Genesis IPG Spinal Cord Stimulator system

Rebetol receives Japanese approval for use in combination with Intron A for hepatitis C

AASLD news: Gilead's adefovir dipivoxil improves liver function and reduces viral load in HBV

Design and biological activity of new camptothecin glycoconjugates described by Bayer

Accelerated progress marks Q3 at Xenova

Primary endpoint of large tifacogin trial in sepsis patients not met according to Chiron

Specific activation of amygdala neurons and brain penetration demonstrated for secretin

Interim report shows British Biotech continues to make good progress

Preclinical data support use of dexanabinol in neuroinflammatory disorders

Antimalarial prodrugs in development at Jacobus

Successful human somatic cell nuclear transfer and parthenogenesis

Second conference on neuroimmunophilins held during SFN meeting

Abbott continues to pursue highly selective ETA receptor antagonists

Introduction of SynX's diagnostic aid for Alzheimer's disease

M-55113: an anticoagulant factor Xa inhibitor designed at Mochida

New product significantly reduces the risk of AMD

Abbott's acquisition of Vysis clears antitrust review

Specific inhibition of MMP-2 binding to alphavbeta3 integrin for inhibiting angiogenesis

Antitumor sulfonamide derivatives reported in recent patent by Sankyo

Protein tyrosine kinase inhibitors from AHP exert antitumor activity in vitro

Lactam inhibitors of Abeta peptide and their use in Alzheimer's disease and related disorders

ADIR prepares inhibitors of monoamine reuptake for CNS disorders

New gastric antisecretory agents designed by Byk Gulden

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...